The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Approval strengthens the company’s growing international anti-infective portfolio
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
The standout story remains Wegovy, particularly its new oral formulation
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
Subscribe To Our Newsletter & Stay Updated
